Alzheimer’s Drug AL002 Shows Promise, But Falls Short in Key Trial A new experimental treatment for early Alzheimer’s disease, the TREM2 agonistic antibody AL002, has demonstrated it can engage its target within the brain, offering a glimmer of hope in the fight against this devastating condition. However, a recently completed phase 2 clinical trial revealed … Read more
A comprehensive study published in Nature details the intricate interplay between the nervous system, the microbiome, and lung cancer development, revealing a surprising role for vagal sensory neurons (VSNs) in modulating tumor growth and immune response. This research, utilizing sophisticated mouse models and bolstered by analysis of human lung adenocarcinoma (LUAD) data, doesn’t just identify … Read more
For decades, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has been dismissed as a psychological ailment, leaving millions suffering without validation or effective treatment. That paradigm is now facing a significant challenge. Groundbreaking research from Griffith University has identified a consistent biological feature in ME/CFS patients: a malfunction in the TRPM3 ion channel, responsible for crucial calcium … Read more
Breakthrough CAR T-Cell Therapy Shows Promise for Generalized Myasthenia Gravis In a landmark clinical trial, a novel CAR T-cell therapy engineered with mRNA technology has demonstrated significant efficacy in treating generalized myasthenia gravis (GMG). The findings, revealed today, offer a potential new avenue of hope for individuals battling this debilitating autoimmune disorder. A randomized, double-blind, … Read more